Meeting
2016 ASCO Annual Meeting
HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
Authors
Alessandra Landmann
University of Pittsburgh Medical Center, Pittsburgh, PA
Alessandra Landmann , Daniel J. Farrugia , Emilia Diego , Marguerite Bonaventura , Atilla Soran , Ronald Johnson , David J. Dabbs , Beth Clark , Adam Brufsky , Nancy E. Davidson , Barry C. Lembersky , Rachel Catherine Jankowitz , Shannon Puhalla , Gretchen M. Ahrendt , Priscilla F. McAuliffe , Rohit Bhargava
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 612)
DOI
10.1200/JCO.2016.34.15_suppl.612
Abstract #
612
Poster Bd #
100
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
First Author: Christian F. Singer
Poster
2023 ASCO Annual Meeting
Impact of race on BluePrint genomic subtyping in HER2+ breast cancer.
First Author: Sonya A. Reid
First Author: Natália Polidorio
Poster
2022 ASCO Annual Meeting
DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.
First Author: Veronique Debien